Benefits
Memory and cognitive performance
Cognivia® has demonstrated significant working memory and accuracy improvements in a 29-day RCT in healthy adults aged 30–60 (n=94), with effects strongest at day 29 indicating cumulative benefit. A second crossover study showed acute benefits on numeric working memory and reaction time during physical exercise. Generic Salvia officinalis extract has also shown acute memory enhancement in healthy adults across multiple smaller crossover trials.
Alzheimer's disease cognitive support
A 16-week RCT in 42 mild-to-moderate Alzheimer's patients (Akhondzadeh 2003) found Salvia officinalis ethanolic tincture significantly improved cognitive function on the ADAS-cog scale (p=0.037) and Clinical Dementia Rating (p=0.001) compared to placebo, with effect sizes comparable to early-stage cholinesterase inhibitor pharmacotherapy. The acetylcholinesterase inhibition mechanism directly targets the cholinergic deficit driving Alzheimer's symptomatology. Note: this evidence is for generic Salvia officinalis extract, not the Cognivia® formulation specifically.
Mood and reduced anxiety
Sage supplementation has shown significant mood improvements in healthy adults — increasing alertness, calmness, and contentedness on the Bond-Lader mood scales, with reduced anxiety in some doses (Kennedy et al. 2006). Effects are attributed to a combination of cholinergic enhancement and GABA-A receptor modulation by sage monoterpenes. Note: most mood evidence is for generic Salvia species, not the Cognivia® formulation specifically.
Antioxidant and anti-aging neuroprotection
Carnosic acid and carnosol from sage are extremely potent lipophilic antioxidants that cross the blood-brain barrier and protect neuronal lipid membranes from oxidative damage. These neuroprotective polyphenols complement the acetylcholinesterase inhibition mechanism, providing both symptomatic and protective benefits for cognitive aging.
Mechanism of action
Acetylcholinesterase inhibition
Sage extract — particularly its monoterpene fraction (1,8-cineole, α-thujone, camphor) — inhibits acetylcholinesterase in a dose-dependent, reversible manner. This increases synaptic acetylcholine availability in hippocampal and cortical circuits governing learning and memory, explaining the acute memory improvements observed within 1 hour of supplementation.
Nicotinic and muscarinic receptor binding
Sage constituents directly bind nicotinic (nAChR) and muscarinic (mAChR) acetylcholine receptors — both the inhibitory (M2/M4) and excitatory (M1/M3) subtypes — producing net cholinergic enhancement through receptor activation alongside enzyme inhibition. This dual mechanism explains effects broader than acetylcholinesterase inhibition alone.
GABA-A receptor modulation and anxiolytic activity
Sage monoterpenes (particularly linalool and borneol) act as positive allosteric modulators at GABA-A receptors in vitro and in animal models — the same receptor class targeted by benzodiazepines, but with lower affinity and without dependency risk. This GABAergic mechanism may contribute to the calming effects observed in some sage trials, though direct evidence in humans is limited.
Clinical trials
Randomized, double-blind, placebo-controlled, parallel-group trial of Cognivia® (600 mg/day, containing 400 mg Salvia officinalis polyphenols + 50 µL Salvia lavandulaefolia essential oil) vs. placebo in 94 healthy adults aged 30–60 for 29 days. Conducted at Northumbria University, sponsored by Nexira.
94 healthy adults aged 30–60 (69 female, 25 male). 29-day intervention with assessments at 120 and 240 min post-dose on day 1 and day 29.
Cognivia® produced consistent, significant benefits on working memory and accuracy outcomes (Corsi Blocks, Numeric Working Memory, Name to Face Recall) both acutely (within day 1) and chronically (after 29 days). The chronic cumulative benefit was strongest, suggesting sustained engagement of cholinergic and antioxidant pathways. Well-tolerated with no significant adverse events.
Randomized, double-blind, placebo-controlled, crossover trial of Cognivia® (600 mg single dose) vs. placebo in healthy active adults during intense physical activity. Conducted by INSERM (French National Institute of Health and Medical Research), published in Frontiers.
94 healthy adults (25 men, 69 women, ages 30–60). Randomized, double-blind, placebo-controlled, parallel-groups design; 600 mg/day Cognivia™ (400 mg S. officinalis aqueous extract + 50 µL S. lavandulaefolia essential oil) vs placebo for 29 days. Cognitive battery (COMPASS) at days 1 and 29, 120 and 240 min post-dose.
Cumulative benefits of Cognivia™ on accuracy and working memory cognitive domains over 29 days. Acute and chronic cognitive enhancement demonstrated. First human RCT of combined S. officinalis polyphenols + S. lavandulaefolia terpenoids. Industry-funded (Nexira SAS).
Randomized, double-blind, placebo-controlled trial of Salvia officinalis ethanolic extract tincture (60 drops/day) vs. placebo in 42 patients with mild-to-moderate Alzheimer's disease for 16 weeks. (Akhondzadeh et al. 2003) Note: this trial used generic Salvia officinalis extract, not Cognivia® specifically.
42 patients with mild-to-moderate Alzheimer's disease. 16-week intervention.
Sage extract produced significantly better cognitive function on the ADAS-cog scale and Clinical Dementia Rating compared to placebo (p=0.037 for ADAS-cog, p=0.001 for CDR). Reduced agitation. Well-tolerated with no significant adverse effects. Supports sage as adjunct in Alzheimer's management; effect size comparable to early-stage cholinesterase inhibitor pharmacotherapy.